🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

Found 29 matching trials

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

The primary purpose of this study is to demonstrate the equivalence of bude...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-10-17

Trial ID

NCT06340581

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu Spacer

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4

The goal of this clinical trial is to determine if triple inhaled therapy w...

Status

Completed

Location

Narongkorn Saiphoklang

Start Date

2025-04-01

Trial ID

NCT06905483

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol (BGF)Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

PHASE3

This study will investigate the effect of Budesonide, Glycopyrronium, and F...

Status

Completed

Location

Research Site

Start Date

2023-10-24

Trial ID

NCT06067828

Treatments Being Tested

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Treatment B: Budesonide and Formoterol Fumarate Treatment C : Placebo

Early Screening of Young COPD and Pre-COPD

N/A

At present, patients with early COPD and pre-COPD have not been paid attent...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2025-03-01

Trial ID

NCT06844175

Treatments Being Tested

Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol

Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD

N/A

The purpose of this study is to describe patients' clinical and self-report...

Status

Completed

Location

Research Site

Start Date

2024-04-30

Trial ID

NCT06368427

Treatments Being Tested

budesonide / glycopyrronium / formoterol

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

PHASE3

The purpose of this study is to demonstrate that the lung function effect f...

Status

Completed

Location

Research Site

Start Date

2024-01-11

Trial ID

NCT06075095

Treatments Being Tested

BGF MDI HFO 320/14.4/9.6μg BGF MDI HFA 320/14.4/9.6 μg Placebo MDI HFA

REported Outcomes in COPD With Trixeo in Real worlD

N/A

Chronic obstructive pulmonary disease (COPD) is characterized by persistent...

Status

Completed

Location

Research Site

Start Date

2022-08-11

Trial ID

NCT05213611

Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

PHASE1

Multicentre, prospective, non-randomised, single-arm, open label, mechanist...

Status

Recruiting

Location

CHU de Lille

Start Date

2023-09-29

Trial ID

NCT06110403

Treatments Being Tested

TRIXEO AEROSPHERE

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

PHASE1

A study to assess the pharmacokinetics and safety of two doses of PT010 and...

Status

Completed

Location

Research Site

Start Date

2017-04-17

Trial ID

NCT03075267

Treatments Being Tested

PT010 (BGF MDI) 320/14.4/9.6 µg PT010 (BGF MDI) 160/14.4/9.6 µg PT003 (GFF MDI) 14.4/9.6 µg

Previous Next